Roche pays $200M for rights to Dicerna's hepatitis B RNAi drug

Roche pays $200M for rights to Dicerna's hepatitis B RNAi drug

Source: 
Fierce Biotech
snippet: 

Roche is paying Dicerna Pharmaceuticals $200 million (€179 million) upfront for a global license to phase 1 hepatitis B prospect DCR-HBVS. The deal, which will see Roche and Dicerna collaborate on other hepatitis B virus assets, is worth up to $1.5 billion in milestones.